contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


fluoguide-wrap-up-from-introduction-to-the-company

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Henrik Ekman

CEO, Sweden

Claus Thestrup

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

FluoGuide

Interview with CEO Morten Albrechtsen about the pipeline and opportunities

Investor interest should focus on how Fluoguide pipeline progresses, specifically regarding its most important pipeline project, FG001, currently in phase 2 and designed to increase the efficiency of various forms of cancer surgeries, the first indication being aggressive brain cancer (glioblastoma), but it is also tested in head-and-neck and lung cancer. Also, an update on the recent announcement of FG001 in combination with Photothermal Therapy (PTT) is important.
&nbsp;FG001 for glioblastoma is a compound that is injected into the person that lights up cancer cells in the brain and increases the likelihood that the surgeon will be able to better identify and therefore remove more - or all - of the cancer cells with less side effects resulting in the potential of a complete cure of the patient and lower healthcare cost longer term. While potentially very efficient, recently published topline data from a phase IIb study cancer cell November 2023 indicates that FG001 is not statistically significantly different compared to a competing product (Gleolan) already approved that similarly lights up cancer cells for better guided surgeries.&nbsp;
To increase the chance for a study that shows data which are positively statistically significant, Fluoguide announced on January 8th, 2024, that they will test FG001 in combination with PTT to potentially eliminate the cancer cells when FG001 is being used as guidance. This means the progress developing FG001 will be delayed but the far more valuable commercialization potential of combining FG001 and PTT will be brought forward. The new study is expected to start in 2025.
Watch the full interview here: <a href="https://www.youtube.com/watch?v=G44TMuaWO2s" target="_blank" rel="noopener">Introduction to Fluoguide</a>
Disclaimer:&nbsp;HC Andersen Capital receives payment from Fluoguide for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup&nbsp;1:10 PM 05-03-2024.&nbsp;